The CEO of ZZ Biotech outlined the design of the phase 2 trial of 3KA-APC, which will enroll 16 patients with amyotrophic lateral sclerosis. [WATCH TIME: 4 minutes]
Kent Pryor, PhD
Advertisement
Kent Pryor, PhD, CEO ZZ Biotech
Articles by Kent Pryor, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Early Results Show Symptom Gains in First Patient Dosed With UX-DA001 Cell Therapy for Parkinson Disease
2
Bringing Biomarkers to the Bedside: The Clinical Promise of Abbott’s TBI Test
3
Understanding Key Clinical and Genetic Biomarkers in Huntington Disease Research: Sarah O'Shea, MD, MSc
4
De-Escalation Strategies in Multiple Sclerosis: Oral Therapies and Cladribine
5
